| The consensus molecular subtypes of colorectal cancer J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ... Nature medicine 21 (11), 1350-1356, 2015 | 4684 | 2015 |
| Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ... The lancet oncology 18 (9), 1182-1191, 2017 | 2590 | 2017 |
| Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ... Journal of clinical oncology 36 (8), 773-779, 2018 | 1939 | 2018 |
| Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy S Kopetz, GJ Chang, MJ Overman, C Eng, DJ Sargent, DW Larson, ... Journal of clinical oncology 27 (22), 3677-3683, 2009 | 1533 | 2009 |
| Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours J Galon, B Mlecnik, G Bindea, HK Angell, A Berger, C Lagorce, A Lugli, ... The Journal of pathology 232 (2), 199-209, 2014 | 1505 | 2014 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1275 | 2019 |
| Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer R Dienstmann, L Vermeulen, J Guinney, S Kopetz, S Tejpar, J Tabernero Nature reviews cancer 17 (2), 79-92, 2017 | 965 | 2017 |
| Cancer classification using the Immunoscore: a worldwide task force J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ... Journal of translational medicine 10, 1-10, 2012 | 958 | 2012 |
| Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer B Tran, S Kopetz, J Tie, P Gibbs, ZQ Jiang, CH Lieu, A Agarwal, DM Maru, ... Cancer 117 (20), 4623-4632, 2011 | 834 | 2011 |
| Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ... Journal of clinical oncology 33 (34), 4032-4038, 2015 | 739 | 2015 |
| Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases DG Blazer III, Y Kishi, DM Maru, S Kopetz, YS Chun, MJ Overman, ... Journal of Clinical Oncology 26 (33), 5344-5351, 2008 | 683 | 2008 |
| CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ... Genome research 23 (9), 1446-1461, 2013 | 682 | 2013 |
| Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for … AR Sepulveda, SR Hamilton, CJ Allegra, W Grody, AM Cushman-Vokoun, ... American journal of clinical pathology 147 (3), 221-260, 2017 | 656 | 2017 |
| Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests RFA Logan, J Patnick, C Nickerson, L Coleman, MD Rutter, ... Gut 61 (10), 1439-1446, 2012 | 600 | 2012 |
| Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis, K Yamazaki, RH Xu, ... Annals of Oncology 29 (1), 44-70, 2018 | 566 | 2018 |
| Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases YS Chun, JN Vauthey, P Boonsirikamchai, DM Maru, S Kopetz, ... Jama 302 (21), 2338-2344, 2009 | 549 | 2009 |
| Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer RB Corcoran, CE Atreya, GS Falchook, EL Kwak, DP Ryan, JC Bendell, ... Journal of clinical oncology 33 (34), 4023-4031, 2015 | 544 | 2015 |
| Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with … S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ... Journal of clinical oncology 28 (3), 453-459, 2010 | 541 | 2010 |
| Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). S Kopetz, SL McDonough, VK Morris, HJ Lenz, AM Magliocco, CE Atreya, ... Journal of Clinical Oncology 35 (4_suppl), 520-520, 2017 | 441* | 2017 |
| KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer W Liao, MJ Overman, AT Boutin, X Shang, DI Zhao, P Dey, J Li, G Wang, ... Cancer cell 35 (4), 559-572. e7, 2019 | 440 | 2019 |
Van MorrisMD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
